Member Info for beinthelead

Think this was he; https://mobile.twitter.com/lee_williams97

Totally agree. Unbelievable how ignorant these comments are. Any trust/credibility left with the Medusa ramped fiasco.

There’s nothing special or clever been done, Avacta’s side. They knee jerked and shoe horned an affimer into the Mologic test. It’s identical.

AS almost admitted that they will design the test as they always wanted - Affimer driven. ‘We’ve learnt a lot about the process’ etc. they’ve now the time to do it right. Or risk the entire Dx division if they don’t.

Finally a sensible post.

I’d say they’ve sold Zoom. Too proud/embarrassed to report so on here. Not that they should report anything.

Two years plus is a long time in AIM. Some people
need the money. Taking it now must be soul destroying. No wonder people turn bitter and go all ‘Bishop’.

They’re not triggering stop losses. The MM’s aren’t the devil. The market is red.

What do you mean?

Exactly. They’re not a tin pot outfit - they are two companies, effectively. Loads of people and resource. They need to fix this one first. Any development of new tests will be undermined unless they do.

*not being

No, it’s not. Whatever other tests do is up to them. Our test has failed due to Omicron impact. I’m being inflammatory.

I’m past the opportunity for the time being. It’s more important they show they can fix the test, and get Medusa back up and running. Let it simmer, develop further AffiDX tests. A failed test is not a good advert for the division.

A Dx bullish, PL. We’re back in the game.

Yeah, appears so. That LittleGunner account was the most obvious tribal ramper. ‘Tis odd.

It’s a boring watch at the moment. Even consecutive blue days (not many!) aren’t a sure sign of a lift. Others are in control of the slide at the mo.

Come on Rip, Bishop is back - didn’t you know??

https://twitter.com/Bish0p5022/status/1495669545817759751?s=20&t=4S87whlvRExqDVZCAeMjHw

Also missed the point that patients are tested for active FAP expression before the trial.

Just rewatched Fiona Mc on the Vix market video.

‘[this is] the first time there’s fine clinical data on a [FAP] targeted doxorubicin’s molecule’

Once published, and IF positive, this abundance of data from the P1 trials will spread like wild fire.

Has anyone got access to that deleted Vox interview that stated Avacta would be worth 4-5bn if it was listed in the US?

Thanks.

There’s few genuine folks around. Especially after this expose. Nice work.

Ah… nice he got exposed the other night, too. TW is some guy.

Rip - please remain a constant.

Good find.